Similar articles for PMID: 26075276

Year	Number of Results
1989	1
1991	1
1993	3
1994	1
1995	2
1996	3
1997	2
1998	3
1999	3
2001	3
2002	1
2003	2
2005	3
2006	4
2007	6
2008	4
2009	3
2010	2
2011	3
2012	4
2013	6
2014	4
2015	10
2016	7
2017	7
2018	8
2019	7
2020	7
2021	4
2022	2
2024	2

1

Risk factors and scoring system for predicting bacterial resistance to cefepime as used empirically in haematology wards.

El Maaroufi H, Goubard A, Redjoul R, Legrand P, Pautas C, Mikdame M, Doghmi K, Toma A, Maury S, Schwarzinger M, Cordonnier C. El Maaroufi H, et al. Biomed Res Int. 2015;2015:945769. doi: 10.1155/2015/945769. Epub 2015 May 5. Biomed Res Int. 2015. PMID: 26075276 Free PMC article. Clinical Trial.

2

Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study.

Alves MD, Ribeiro VB, Tessari JP, Mattiello F, De Bacco G, Luz DI, Vieira FJ, Behle TF, Pasqualotto AC, Zavascki AP. Alves MD, et al. J Antimicrob Chemother. 2014 Jun;69(6):1681-7. doi: 10.1093/jac/dku001. Epub 2014 Jan 27. J Antimicrob Chemother. 2014. PMID: 24474430

3

Low-dosage cefepime as treatment for serious bacterial infections.

Giamarellou H. Giamarellou H. J Antimicrob Chemother. 1993 Nov;32 Suppl B:123-32. doi: 10.1093/jac/32.suppl_b.123. J Antimicrob Chemother. 1993. PMID: 8150755 Clinical Trial.

4

Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms.

Bhat SV, Peleg AY, Lodise TP Jr, Shutt KA, Capitano B, Potoski BA, Paterson DL. Bhat SV, et al. Antimicrob Agents Chemother. 2007 Dec;51(12):4390-5. doi: 10.1128/AAC.01487-06. Epub 2007 Oct 15. Antimicrob Agents Chemother. 2007. PMID: 17938179 Free PMC article.

5

Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.

Chopra T, Marchaim D, Veltman J, Johnson P, Zhao JJ, Tansek R, Hatahet D, Chaudhry K, Pogue JM, Rahbar H, Chen TY, Truong T, Rodriguez V, Ellsworth J, Bernabela L, Bhargava A, Yousuf A, Alangaden G, Kaye KS. Chopra T, et al. Antimicrob Agents Chemother. 2012 Jul;56(7):3936-42. doi: 10.1128/AAC.05419-11. Epub 2012 Apr 30. Antimicrob Agents Chemother. 2012. PMID: 22547616 Free PMC article.

6

Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC.

Rhodes NJ, Liu J, McLaughlin MM, Qi C, Scheetz MH. Rhodes NJ, et al. Diagn Microbiol Infect Dis. 2015 Jun;82(2):165-71. doi: 10.1016/j.diagmicrobio.2015.03.005. Epub 2015 Mar 10. Diagn Microbiol Infect Dis. 2015. PMID: 25801780

7

Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.

Chong Y, Shimoda S, Yakushiji H, Ito Y, Miyamoto T, Kamimura T, Shimono N, Akashi K. Chong Y, et al. PLoS One. 2013;8(1):e54190. doi: 10.1371/journal.pone.0054190. Epub 2013 Jan 23. PLoS One. 2013. PMID: 23372683 Free PMC article. Clinical Trial.

8

Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.

Deal EN, Micek ST, Reichley RM, Ritchie DJ. Deal EN, et al. Clin Ther. 2009 Feb;31(2):299-310. doi: 10.1016/j.clinthera.2009.02.015. Clin Ther. 2009. PMID: 19302902 Clinical Trial.

9

Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.

Moghnieh R, Estaitieh N, Mugharbil A, Jisr T, Abdallah DI, Ziade F, Sinno L, Ibrahim A. Moghnieh R, et al. Front Cell Infect Microbiol. 2015 Feb 12;5:11. doi: 10.3389/fcimb.2015.00011. eCollection 2015. Front Cell Infect Microbiol. 2015. PMID: 25729741 Free PMC article.

10

Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms.

McKamey L, Venugopalan V, Cherabuddi K, Borgert S, Voils S, Shah K, Klinker KP. McKamey L, et al. Int J Antimicrob Agents. 2018 Nov;52(5):719-723. doi: 10.1016/j.ijantimicag.2018.08.007. Epub 2018 Aug 17. Int J Antimicrob Agents. 2018. PMID: 30125680

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year